坦桑尼亚儿童和青少年在多路替格雷韦抗逆转录病毒治疗方案中与病毒载量抑制相关的因素:一项纵向分析

IF 2.5 4区 医学 Q3 INFECTIOUS DISEASES
Abdallah Abtwalibe Maghembe, Marion Sumari-de Boer, Mtoro J Mtoro, Michael Johnson Mahande
{"title":"坦桑尼亚儿童和青少年在多路替格雷韦抗逆转录病毒治疗方案中与病毒载量抑制相关的因素:一项纵向分析","authors":"Abdallah Abtwalibe Maghembe, Marion Sumari-de Boer, Mtoro J Mtoro, Michael Johnson Mahande","doi":"10.1186/s12981-025-00780-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Antiretroviral therapy (ART) reduces morbidity and mortality due to human immunodeficiency virus (HIV) infection. In 2019, Tanzania adopted Dolutegravir (DTG) as a first-, second-line, and third-line treatment for children and adolescents living with HIV (CALHIV). Viral load suppression (VLS) is desirable in the prevention of HIV transmission thus achieving the third '95' target. DTG treatment has highly potent antiviral activity, a high genetic barrier to resistance, and a high safety profile. We aimed to determine VLS and associated factors among CALHIV on DTG-based ART in Tanzania.</p><p><strong>Methods: </strong>We conducted a retrospective cohort analysis among CALHIV who were on a DTG-based regimen in Tanzania between 2019 and 2021. We extracted demographic and clinical characteristics from the care and treatment clinic database. A multilevel mixed effects Poisson regression model was used to determine factors associated with VLS at < 1000 copies/ml among CALHIV on a DTG-based regimen.</p><p><strong>Results: </strong>A total of 63,453 CALHIV on a DTG-based regimen were analysed. The proportion of viral suppression was 91.64%. Overall, 66.19% of previously unsuppressed individuals became suppressed, and 88.45% of previously suppressed remained suppressed. Factors leading to higher chances of viral suppression were aged 15-19 years (aRR: 1.02; 95%CI: 1.017-1.03), those in WHO stage I (aRR: 1.03; 95%CI: 1.01-1.04), those in WHO stage II (aRR: 1.02; 95%CI: 1.00-1.04), and those who ever received a multi-month prescription on ART (aRR: 1.25; 95% CI: 1.23-1.28), while those aged 10-14 years (aRR: 0.98; 95%CI: 0.97-0.99), previously unsuppressed prior to starting DTG (aRR: 0.92; 95%CI: 0.91-0.93), duration on ART more than 24 months (aRR: 0.96; 95%CI: 0.94-0.97), not retained in care (aRR: 0.83; 95% CI: 0.77-0.89), severe malnutrition (aRR:0.77; 95%CI: 0.69-0.94) and coastal zone (aRR: 0.98; 95% CI: 0.96-0.99) were less likely to achieve VLS.</p><p><strong>Conclusions: </strong>This study showed DTG-based regimens have a good response for both naïve, previously unsuppressed, and suppressed Children and Adolescents Living with HIV (CALHIV) with significant improvement in viral suppression. Improving retention in care and malnutrition might improve VLS and achieve the third '95'.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":"22 1","pages":"82"},"PeriodicalIF":2.5000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12376318/pdf/","citationCount":"0","resultStr":"{\"title\":\"Factors associated with viral load suppression among children and adolescents on dolutegravir-based antiretroviral regimen in Tanzania: a longitudinal analysis.\",\"authors\":\"Abdallah Abtwalibe Maghembe, Marion Sumari-de Boer, Mtoro J Mtoro, Michael Johnson Mahande\",\"doi\":\"10.1186/s12981-025-00780-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Antiretroviral therapy (ART) reduces morbidity and mortality due to human immunodeficiency virus (HIV) infection. In 2019, Tanzania adopted Dolutegravir (DTG) as a first-, second-line, and third-line treatment for children and adolescents living with HIV (CALHIV). Viral load suppression (VLS) is desirable in the prevention of HIV transmission thus achieving the third '95' target. DTG treatment has highly potent antiviral activity, a high genetic barrier to resistance, and a high safety profile. We aimed to determine VLS and associated factors among CALHIV on DTG-based ART in Tanzania.</p><p><strong>Methods: </strong>We conducted a retrospective cohort analysis among CALHIV who were on a DTG-based regimen in Tanzania between 2019 and 2021. We extracted demographic and clinical characteristics from the care and treatment clinic database. A multilevel mixed effects Poisson regression model was used to determine factors associated with VLS at < 1000 copies/ml among CALHIV on a DTG-based regimen.</p><p><strong>Results: </strong>A total of 63,453 CALHIV on a DTG-based regimen were analysed. The proportion of viral suppression was 91.64%. Overall, 66.19% of previously unsuppressed individuals became suppressed, and 88.45% of previously suppressed remained suppressed. Factors leading to higher chances of viral suppression were aged 15-19 years (aRR: 1.02; 95%CI: 1.017-1.03), those in WHO stage I (aRR: 1.03; 95%CI: 1.01-1.04), those in WHO stage II (aRR: 1.02; 95%CI: 1.00-1.04), and those who ever received a multi-month prescription on ART (aRR: 1.25; 95% CI: 1.23-1.28), while those aged 10-14 years (aRR: 0.98; 95%CI: 0.97-0.99), previously unsuppressed prior to starting DTG (aRR: 0.92; 95%CI: 0.91-0.93), duration on ART more than 24 months (aRR: 0.96; 95%CI: 0.94-0.97), not retained in care (aRR: 0.83; 95% CI: 0.77-0.89), severe malnutrition (aRR:0.77; 95%CI: 0.69-0.94) and coastal zone (aRR: 0.98; 95% CI: 0.96-0.99) were less likely to achieve VLS.</p><p><strong>Conclusions: </strong>This study showed DTG-based regimens have a good response for both naïve, previously unsuppressed, and suppressed Children and Adolescents Living with HIV (CALHIV) with significant improvement in viral suppression. Improving retention in care and malnutrition might improve VLS and achieve the third '95'.</p>\",\"PeriodicalId\":7503,\"journal\":{\"name\":\"AIDS Research and Therapy\",\"volume\":\"22 1\",\"pages\":\"82\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12376318/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AIDS Research and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12981-025-00780-2\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS Research and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12981-025-00780-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

简介:抗逆转录病毒疗法(ART)降低了由于人类免疫缺陷病毒(HIV)感染引起的发病率和死亡率。2019年,坦桑尼亚将Dolutegravir (DTG)作为感染艾滋病毒(CALHIV)的儿童和青少年的一线、二线和三线治疗药物。病毒载量抑制(VLS)在预防艾滋病毒传播方面是可取的,从而实现了第三个“95”目标。DTG治疗具有很强的抗病毒活性,对耐药性具有很高的遗传屏障,并且具有很高的安全性。我们的目的是确定坦桑尼亚基于dtg的ART治疗中CALHIV的VLS和相关因素。方法:我们对2019年至2021年在坦桑尼亚接受dtg治疗的CALHIV患者进行了回顾性队列分析。我们从护理和治疗诊所数据库中提取了人口统计学和临床特征。使用多水平混合效应泊松回归模型来确定与VLS相关的因素。结果:在基于dtg的方案中,共分析了63,453例CALHIV。病毒抑制率为91.64%。总体而言,66.19%先前未被压抑的个体变得压抑,88.45%先前被压抑的个体仍然被压抑。导致病毒抑制机会较高的因素是15-19岁(aRR: 1.02; 95%CI: 1.01-1.04)、WHO I期(aRR: 1.03; 95%CI: 1.01-1.04)、WHO II期(aRR: 1.02; 95%CI: 1.00-1.04)和曾经接受过数月抗逆转录病毒治疗的患者(aRR: 1.25; 95%CI: 1.23-1.28),而10-14岁(aRR: 0.98; 95%CI: 0.97-0.99)、开始DTG前未被抑制(aRR: 0.92; 95%CI: 0.91-0.93)、抗逆转录病毒治疗持续时间超过24个月(aRR: 0.96;95%CI: 0.94-0.97),未保留护理(aRR: 0.83; 95%CI: 0.77-0.89),严重营养不良(aRR:0.77; 95%CI: 0.69-0.94)和沿海地区(aRR: 0.98; 95%CI: 0.96-0.99)实现VLS的可能性较小。结论:该研究显示,基于dtg的方案对naïve、先前未抑制和抑制的儿童和青少年HIV感染者(CALHIV)都有良好的反应,病毒抑制显著改善。改善护理留置和营养不良可能会改善VLS,达到第三个95。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Factors associated with viral load suppression among children and adolescents on dolutegravir-based antiretroviral regimen in Tanzania: a longitudinal analysis.

Factors associated with viral load suppression among children and adolescents on dolutegravir-based antiretroviral regimen in Tanzania: a longitudinal analysis.

Factors associated with viral load suppression among children and adolescents on dolutegravir-based antiretroviral regimen in Tanzania: a longitudinal analysis.

Factors associated with viral load suppression among children and adolescents on dolutegravir-based antiretroviral regimen in Tanzania: a longitudinal analysis.

Introduction: Antiretroviral therapy (ART) reduces morbidity and mortality due to human immunodeficiency virus (HIV) infection. In 2019, Tanzania adopted Dolutegravir (DTG) as a first-, second-line, and third-line treatment for children and adolescents living with HIV (CALHIV). Viral load suppression (VLS) is desirable in the prevention of HIV transmission thus achieving the third '95' target. DTG treatment has highly potent antiviral activity, a high genetic barrier to resistance, and a high safety profile. We aimed to determine VLS and associated factors among CALHIV on DTG-based ART in Tanzania.

Methods: We conducted a retrospective cohort analysis among CALHIV who were on a DTG-based regimen in Tanzania between 2019 and 2021. We extracted demographic and clinical characteristics from the care and treatment clinic database. A multilevel mixed effects Poisson regression model was used to determine factors associated with VLS at < 1000 copies/ml among CALHIV on a DTG-based regimen.

Results: A total of 63,453 CALHIV on a DTG-based regimen were analysed. The proportion of viral suppression was 91.64%. Overall, 66.19% of previously unsuppressed individuals became suppressed, and 88.45% of previously suppressed remained suppressed. Factors leading to higher chances of viral suppression were aged 15-19 years (aRR: 1.02; 95%CI: 1.017-1.03), those in WHO stage I (aRR: 1.03; 95%CI: 1.01-1.04), those in WHO stage II (aRR: 1.02; 95%CI: 1.00-1.04), and those who ever received a multi-month prescription on ART (aRR: 1.25; 95% CI: 1.23-1.28), while those aged 10-14 years (aRR: 0.98; 95%CI: 0.97-0.99), previously unsuppressed prior to starting DTG (aRR: 0.92; 95%CI: 0.91-0.93), duration on ART more than 24 months (aRR: 0.96; 95%CI: 0.94-0.97), not retained in care (aRR: 0.83; 95% CI: 0.77-0.89), severe malnutrition (aRR:0.77; 95%CI: 0.69-0.94) and coastal zone (aRR: 0.98; 95% CI: 0.96-0.99) were less likely to achieve VLS.

Conclusions: This study showed DTG-based regimens have a good response for both naïve, previously unsuppressed, and suppressed Children and Adolescents Living with HIV (CALHIV) with significant improvement in viral suppression. Improving retention in care and malnutrition might improve VLS and achieve the third '95'.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
AIDS Research and Therapy
AIDS Research and Therapy INFECTIOUS DISEASES-
CiteScore
3.80
自引率
4.50%
发文量
51
审稿时长
16 weeks
期刊介绍: AIDS Research and Therapy publishes articles on basic science, translational, clinical, social, epidemiological, behavioral and educational sciences articles focused on the treatment and prevention of HIV/AIDS, and the search for the cure. The Journal publishes articles on novel and developing treatment strategies for AIDS as well as on the outcomes of established treatment strategies. Original research articles on animal models that form an essential part of the AIDS treatment research are also considered
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信